Oncology News Articles

▼ Show details

The latest Cancer and Oncology news articles published daily by MDLinx physician editors who comb through the top peer-reviewed clinical journals for the medical articles that will make a difference to you and your practice. Organized by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants can stay current on latest oncology topics, symptoms, treatments, risk factors in Cancer and Hematology.

New! >> Start your free Oncology Board Exam Prep course now.
Ranked, sorted, and summarized by MDLinx editors from the latest literature
Topics:

1 Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): A phase 3, multicentre, randomised trial The Lancet Oncology, November 24, 2014    Clinical Article

2 Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: A phase 1/2 trial The Lancet Oncology, November 24, 2014    Clinical Article

3 Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: Updated results from the phase III HannaH study Annals of Oncology, November 24, 2014    Clinical Article

4 Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expression Cancer Letters, November 24, 2014    Clinical Article

5 American Society of Clinical Oncology policy statement on Medicaid reform Journal of Clinical Oncology, November 24, 2014    Clinical Guideline

6 Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines Journal of Clinical Oncology, November 24, 2014    Clinical Guideline

7 Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: The SPIIN randomized controlled trial Journal of Clinical Oncology, November 24, 2014    Clinical Article

8 Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012 Transfusion, November 24, 2014    Clinical Article

9 The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer Frontiers in Oncology, November 24, 2014    Clinical Article

10 Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis Annals of Oncology, November 24, 2014    Evidence Based Medicine

11 The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men Full Text European Urology, November 24, 2014    Clinical Article

12 Castration-resistant prostate cancer: AUA guideline amendment The Journal of Urology, November 24, 2014    Clinical Guideline

13 Optimisation of fluorescence guidance during robot-assisted laparoscopic sentinel node biopsy for prostate cancer Full Text European Urology, November 24, 2014    Clinical Article

14 Concomitant ALK translocation and EGFR mutation in lung cancer: A comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor Annals of Oncology, November 24, 2014    Clinical Article

15 A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials Annals of Oncology, November 24, 2014    Clinical Article

16 Dexmedetomidine as an adjunctive analgesic with bupivacaine in paravertebral analgesia for breast cancer surgery Full Text Pain Physician, November 24, 2014    Clinical Article

17 Sentinel lymph node and risk factors for predicting metastasis in cutaneous squamous cell carcinoma British Journal of Dermatology, November 24, 2014    Clinical Article

18 Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer Full Text The Oncologist, November 24, 2014    Review Article

19 Chronic thalidomide and chemoembolization for hepatocellular carcinoma Full Text The Oncologist, November 24, 2014    Clinical Article

20 What keeps oncologists from addressing palliative care early on with incurable cancer patients? an active stance seems key Full Text The Oncologist, November 24, 2014    Clinical Article

50 available pages FirstPrevious 1 2 3 4 5 6 7 8 9 10 Next Last

Clinical Pearls in Oncology

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Highlights in Oncology

CTC count predicts survival in mBC

As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).

Increased incidence of second primary cancers in patients with salivary gland tumors

As reported in JAMA—Otolaryngology-Head & Neck Surgery, patients with salivary gland tumors have an increased risk of second primary tumors and newly developed cancers. Specifically, the cumulative 2-, 5-, and 10-year rates for second primary cancers are 4.4%, 8.3%, and 12.4%, respectively. Similarly, the cumulative 2-, 5-, and 10-year rates for newly diagnosed cancers are 1.1%, 3.4%, and 10.5%, respectively.

Cisplatin monotherapy effective in pediatric high-risk hepatoblastoma

As reported in the Journal of Pediatric Hematology/Oncology, treatment of children with high-risk hepatoblastoma (n=14) with cisplatin monotherapy was as effective as cisplatin + doxorubicin combination therapy, but with less toxicity. The complete resection rate was 78.6%, the event-free survival rate was 81.8%, and the OS rate was 100%.


Other Topics in Oncology